Nike, Inc. (NKE)
NYSEConsumer DiscretionaryApparel - Footwear & AccessoriesSnapshot 2026-10-29
$38.42+3.42%
Close 2026-10-29 · 1-day change
NYSEConsumer DiscretionaryApparel - Footwear & AccessoriesSnapshot 2026-10-29
Research Workspace
Put NKE beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Apparel, Accessories & Luxury Goods is in contraction. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Primary pillar under pressure — At least 1% revenue growth: Comparison needs review.
View ThesisRevenue is contracting — down about 1% over the past year.
View GrowthMiddle-of-the-pack quality for its industry.
View QualityManagement screens strong on earnings delivery, the balance sheet.
View ManagementExpectations look high — what the market is pricing in runs ahead of what analysts forecast.
View ValuationThis stock is volatile — it swings about 1% on a typical day and fell roughly 50% in its worst 12-month stretch.
View RiskNike’s turnaround depends on Win Now actions restoring business health as revenue continues to decline. Its latest quarter beat EPS consensus, yet revenue fell 4% year over year. Nike trades at 25× earnings versus the 15× peer median. The market prices more growth than our forecast, leaving expectations full. Fragile cash backing and pressure on revenue growth challenge the turnaround. The primary revenue-growth comparison needs review, so no breach is verified. Our model puts the next-quarter miss probability near 15%. Peer multiples imply a price about 55% below where it trades (it looks expensive on this basis); the thesis is on watch, and this read is provisional.
Trailing returns as of 2026-10-29. NKE is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 46 analysts currently covering NKE (as of Oct 2026).
Based on 22 Wall Street analysts offering 12-month price targets for NKE in the last 4 months.
Continue this research
Compare NKE with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Compare now without an account. Saving and monitoring require an account.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| NKE Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 10 valuation methods, at three horizons. As of 2026-10-29. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Apparel, Accessories & Luxury Goods — fair value, gap to price, and forward P/E.
Compare the value case
Put NKE next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Advances: Win Now actions to improve business
India-specific running shoe supports Win Now growth actions, though one launch is not thesis-changing.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-10-29. EPS is implied from price ÷ P/E. Not investment advice.
Current $38.42
The last 12 months of price, then the range of analyst 12-month targets from today’s $38.42.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Top 25% on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
Advances: Win Now actions to improve business health and quality
Exclusive India running shoe supports Win Now growth efforts and expands local market relevance.
Advances: Win Now actions to improve business health and quality
New India running shoe supports Win Now growth efforts and expands local market relevance.
Threatens: Win Now actions to improve business health and quality
Reported 44% Converse demand decline signals a meaningful brand-health and growth headwind.
Threatens: Win Now actions to improve business health and quality
Ongoing difficulty fixing Converse threatens business quality and growth recovery.
Advances: Win Now actions to improve business health and quality
Citi-reported resale share gains led by Jordan offer evidence of improved brand demand.
Threatens: Win Now actions to improve business health and quality
Lost Foot Locker shelf space points to impaired distribution and business recovery challenges.
BofA downgrade indicates worsening analyst conviction in Nike's recovery prospects.
